Testosterone, dihydrotestosterone, and incident cardiovascular disease and mortality in the cardiovascular health study

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 6, 2014, Pages 2061-2068

  Shores, Molly M ^a,d   Biggs, Mary L ^d   Arnold, Alice M ^c,d   Smith, Nicholas L ^a,b,d   Longstreth Jr , W T ^d   Kizer, Jorge R ^f   Hirsch, Calvin H ^g   Cappola, Anne R ^h   Matsumoto, Alvin M ^a,e  

^a VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^b VA Epidemiologic Research and Information Center   (United States)

^c Geriatric Research Education and Clinical Care (GRECC)   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^f ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTANOLONE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; HEART INFARCTION; HUMAN; LONGITUDINAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; TESTOSTERONE BLOOD LEVEL;

AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; DIHYDROTESTOSTERONE; HUMANS; INCIDENCE; LONGITUDINAL STUDIES; MALE; MORTALITY; RESIDENCE CHARACTERISTICS; RISK FACTORS; TESTOSTERONE;

EID: 84902330217     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-3576     Document Type: Article

References (43)

1. Svartberg J, von Mühlen D, Mathiesen E, Joakimsen O, Bø naa KH, Stensland-Bugge E. Low testosterone levels are associated with carotid atherosclerosis in men. J Intern Med. 2006;259:576-582.
2. Haring R, Baumeister SE, V ölzke H, et al. Prospective association of low total testosterone concentrations with an adverse lipid profile and increased incident dyslipidemia. Eur J Cardiovasc Prev Rehabil. 2011;18:86-96.
3. Maggio M, Basaria S, Ble A, et al. Correlation between testosterone and the inflammatory marker soluble interleukin-6 receptor in older men. J Clin Endocrinol Metab. 2006;91:345-347 .
4. Muller M, Grobbee DE, den Tonkelaar I, Lamberts SW, van der Schouw YT. Endogenous sex hormones and metabolic syndrome in aging men. J Clin Endocrinol Metab. 2005;90:2618-2623.
5. Ruige JB,MahmoudAM,DeBacquer D, Kaufman JM. Endogenous testosterone and cardiovascular disease in healthy men: a meta-analysis. Heart. 2011;97:870-875.
6. Cauley JA Gutai JP Kuller LH Dai WS Usefulness of sex steroid hormone levels in predicting coronary artery disease in men Am J Cardiol. 1987 60 771-777.
7. Contoreggi CS, Blackman MR, Andres R, et al. Pla sma levels of estradiol, testosterone, and DHEAS do not predict risk of coronary artery disease in men. J Androl. 1990;11:460-470.
8. Phillips GB, Yano K, Stemmermann GN. Serum sex hormone levels and myocardial infarction in the Honolulu Heart Program. Pitfalls in prospective studies on sex hormones. J Clin Epidemiol. 1988;41: 1151-1156.
9. Yeap BB, Hyde Z, Almeida OP, et al. Lower testosterone levels predict incident stroke and transient ischemic attack in older men. J Clin Endocrinol Metab. 2009;94:2353-2359.
10. Wehr E, Pilz S, Boehm BO, März W, Grammer T, Obermayer-Pietsch B. Low free testosterone is associated with heart failure mortality in older men referred for coronary angiography. Eur J Heart Fail. 2011;13:482-488.
11. Ponikowska B, Jankowska EA, Maj J, et al. Gonadal and adrenal androgen deficiencies as independent predictors of increased cardiovascular mortality inmenwith type II diabetes mellitus and stable coronary artery disease. Int J Cardiol. 2010;143:343-348.
12. Malkin CJ, Pugh PJ, Morris PD, Asif S, Jones TH, Channer KS. Low serum testosterone and increased mortality in men with coronary heart disease. Heart. 2010;96:1821-1825.
13. Haring R, Vö lzke H, Steveling A, et al.Lowserum testosterone levels are associated with increased risk of mortality in a population-based cohort of men aged 20-79. Eur Heart J. 2010;31:1494-1501.
14. Hyde Z, Norman PE, Flicker L, et al. Low free testosterone predicts mortality from cardiovascular disease but not other causes: the Health in Men Study. J Clin Endocrinol Metab. 2012;97:179-189.
15. Ohlsson C, Barrett-Connor E, Bhasin S, et al. High serum testosterone is associated with reduced risk of cardiovascular events in elderly men. The MrOS (Osteoporotic Fractures in Men) study in Sweden. J Am C oll Cardiol. 2011;58:1674-1681.
16. Laughlin GA, Barrett-Connor E, Bergstrom J. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab. 2008; 93:68-75.
17. Li S, Li X, Li Y. Regulation of atherosclerotic plaque growth and stability by testosterone and its receptor via influence of inflammatory reaction. Vascul Pharmacol. 2008;49:14-18.
18. Littleton-Kearney M, Hurn PD. Testosterone as a modulator of vascular behavior. Biol Res Nurs. 2004;5:276-285.
19. Araujo AB, Kupelian V, Page ST, Handelsman DJ, Bremner WJ, McKin lay JB. Sex steroids and all-cause and cause-specific mortality in men. Arch Intern Med. 2007;167:1252-1260.
20. Yeap BB, Alfonso H, Chubb SA, et al. In older men an optimal plasma testoster one is associated with reduced all-cause mortality and higher dihydrotestosterone with reduced ischemic heart disease mortality, while estradiol levels do not predict mortality. J Clin Endocrinol Metab. 2014;99:E9-E18.
21. Fried LP, Borhani NO, Enright P, et al. The Cardiovascular Health Study: design and rationale. Ann Epidemiol. 1991;1:263-276.
22. Kalhorn TF, Page ST, Howald WN, Mostaghel EA, Nelson PS. Analysis of testosterone and dihydrotestosterone from biological fluids as the oxime derivatives using high-performance liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom. 2007;21:3200-3206.
23. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab. 1999;84:3666-3672.
24. Mazer NA. A novel spreadsheet method for calculating the free serum concentrations of testosterone, dihydrotestosterone, estradiol, estrone and cortisol: with illustrative examples from male and female populations. Steroids. 2009;74: 512-519.
25. Longstreth WT Jr, Bernick C, Fitzpatrick A, et al. Frequency and predictors of stroke death in 5,888 participants in the Cardiovascular Health Study. Neurology. 2001;56:368-375 .
26. Hastie TJ, Tibsharani RJ. 1990 Generalized additive models. Boca Raton: Chapman Hall/CRC.
27. Araujo AB, E sche GR, Kupelian V, et al. Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab. 2007;92: 4241-4247.
28. Soisson V Brailly-Tabard S Helmer C et al.AJ-shaped association between plasma testosterone and risk of ischemic arterial event in elderly men: the French 3C cohort study Maturitas. 2013 75 282-288.
29. Bhasin S, Travison TG, Storer TW, et al. Effect of testosterone supplementation with and without a dual 5-reductase inhibitor on fat-free mass in men with suppressed testosterone production: a randomized controlled trial. JAMA. 2012;307:931-939.
30. Andriole GL, Bostwick DG, BrawleyOW,et al. Effect of dutasteride on the risk of prostate cancer.NEngl J Med. 2010;362:1192-1202.
31. Thompson IM, Good man PJ, Tangen CM, et al. 2003 The influence of finasteride on the development of prostate cancer.NEngl J Med. 349:215-224.
32. Loke YK, Ho R, Smith M, Wong O, Sandhu M, Sage W, Si ngh S. Systematic review evaluating cardiovascular events of the 5-reductase inhibitor- dutasteride. J Clin Pharm Ther. 2013;38:405-415.
33. Akishita M, Hashimoto M, Ohike Y, et al. Low tes tosterone level as a predictor of cardiovascular events in Japanese men with coronary risk factors. Atherosclerosis. 2010;210:232-236.
34. Khaw KT, Dowsett M, Folkerd E, et al. Endogenous testos terone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation. 2007; 116:2694-2701.
35. Menke A, Guallar E, Rohrmann S, et al. Sex steroid hormone concentrations and risk of death in US men. Am J Epidemiol. 2010; 171:583-592.
36. Haring R, Nauck M, Vö lzke H, et al. Low serum testosterone is associated with increased mortality in men with stage 3 or greater nephropathy. Am J Nephrol. 2011;33:209-217.
37. Vikan T, Schirmer H, Nj ølstad I, Svartberg J. Endogenous sex hormones and the prospective association with cardiovascular disease and mortality in men: the Tromsø Study. Eur J Endocrinol. 2009; 161:435-442.
38. Tivesten A, Vandenput L, Labrie F , et al. Low serum testosterone and estradiol predict mortality in elderly men. J Clin Endocrinol Metab. 2009;94:2482-2488.
39. Shores MM, Matsumoto AM, Sloan KL, Kivlahan DR. Low serum testosterone and mortality in male veterans. Arch Intern Med. 2006; 166:1660-1665.
40. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010;95:2536-2559.
41. Vermeulen A, Verdonck G. Representativeness of a single point plasma testosterone level for the long term hormonal milieu in men. J Clin Endocrinol Metab. 1992;74:939-942.
42. Brambil la DJ, MatsumotoAM,Araujo AB, McKinlay JB. The effect of diurnal variation on clinical measurement of serum testosterone and other sex hormone levels in men. J Clin Endocrinol Metab. 2009;94:907-913.
43. Yeap BB, Alfonso H, Chubb SA, et al. Reference ranges and determinants of testosterone, dihydrotestosterone, and estradiol levels measured using liquid chromatography-tandem mass spectrometry in a population-based cohort of older men . J Clin Endocrinol Metab. 2012;97:4030-4039.